NovaBiotics

Name

NovaBiotics

Legal name

NovaBiotics Ltd

Website

https://novabiotics.co.uk

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Antimicrobial peptides
• Cysteamine therapeutics
• Nail health products
• Clinical-stage biotechnology
• Respiratory infection treatments

Headquarters

HQ city

Aberdeen

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Consumer Health Product Sales: Revenue from sales of Tinexyl consumer health products including Tinexyl PRO (B2B through UK podiatrists), Tinexyl-ER, and Tinexyl-XR (consumer formulations). Products distributed globally via Brand Creations Limited with pre-agreed licensing terms including minimum payments and sales royalties.
2. NP213 Licensing Deal: Licensing agreement with undisclosed partner for NP213 peptide topical nail fungus treatment in Europe and Japan (excluding US). NovaBiotics receives development milestone payments prior to launch and sales royalties thereafter.
3. Pharmaceutical Development: Revenue potential from advanced clinical stage assets (NM001 for cystic fibrosis, NM002 for pneumonia) through eventual commercialization, licensing, or acquisition. Products in Phase 3 (REMAP-CAP) and registration trial-ready stages with Orphan Drug Designation and Fast Track Designation from FDA.
4. Government Grants and Funding: Innovate UK funding (£1m) for Nylexa COVID-19 clinical development; MRC grant funding for tuberculosis research with Liverpool School of Tropical Medicine; Department of Health and Social Care funding for NP339 antifungal development.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

NovaBiotics is a clinical-stage biotechnology company operating two divisions. Its Pharma division develops novel cysteamine-based therapies and cationic antimicrobial peptide drug candidates for cystic fibrosis, hospital-acquired pneumonia, fungal infections, and COVID-19. Its Consumer Health division develops and commercializes Tinexyl nail health products, including professional (Tinexyl PRO) and at-home (Tinexyl-ER, Tinexyl-XR) lines.

Product overview

NovaBiotics is a clinical-stage biotechnology company with two divisions: Pharma and Consumer Health. The pharma division develops cysteamine-based therapies (NM001/Lynovex® for cystic fibrosis, NM002/Nylexa® for pneumonia) and novel antimicrobial peptides (NP339 for fungal infections, NP432 for bacterial infections, NP213/Novexatin® for nail fungus). The consumer health division commercializes Tinexyl® nail care products using proprietary TXYL polymer technology and PLK polymers for skin/scalp/hair care. Products range from advanced clinical-stage candidates (NM001, NM002) to commercially available consumer products (Tinexyl® PRO, Tinexyl-ER®, Tinexyl-XR®).

Differentiator

Problem solved

Functional benefit

Brands

• Tinexyl: Nail conditioning and hydrating product range including Tinexyl PRO, Tinexyl-ER, and Tinexyl-XR for toenail health solutions
• Nylexa
• Lynovex
• Novexatin
• Tinexyl PRO

Products and services

• NM001 (Lynovex)

Quantifiable outcome

• 75% of patients reported decreased toenail brittleness, thickening and discomfort at 18-24 weeks of Tinexyl PRO use
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Liverpool School of Tropical Medicine (LSTM)coreStrategic or Co-development Partner · 24 March 2025Collaboration to investigate use of oral cysteamine bitartrate in treatment of mycobacterial disease including tuberculosis (TB). LSTM has world-leading expertise in mycobacterial disease research with access to clinical isolates, tools and models. Goal is to improve patient outcomes by more effectively resolving mycobacterial burden. Currently focused on assessing cysteamine's potentiation of antimicrobial therapies for drug-resistant and drug-sensitive TB strains. MRC grant funding secured for this research.
• Institute of PodiatristsminorChannel Partner/ Reseller/ Distributor · 28 January 2025Professional body endorsing Tinexyl PRO after rigorous assessment by Medicines and Procedures Panel (MaPP) over one year including product trial. Endorsement based on positive trial results published in Podiatry Review. Gaynor Wooldridge, Chair of Executive Committee, stated product may be 'substance of choice for topical nail treatment in the future'.
• Brand Creations LimitedcoreChannel Partner/ Reseller/ Distributor · 8 October 2024Global sales and distribution agreement for Tinexyl nail health products. Brand Creations has global distribution rights excluding Caribbean and B2B UK sales. Tinexyl-ER and Tinexyl-XR launched in US market. Pre-agreed license terms include minimum payments to NCH plus incentives for BCL to drive brand value. BCL team has proven track record scaling health brands including Nutribullet, Proactiv, Zumba via DRTV and digital marketing.
• REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community Acquired Pneumonia)coreStrategic or Co-development Partner · 21 June 2021Global Phase 3 clinical trial evaluating NM002 (IV cysteamine bitartrate) for community acquired pneumonia including COVID-19, influenzas and bacterial pneumonias. Trial conducted at over 300 clinical sites across more than 20 countries worldwide, funded by consortium including UK's NIHR. NovaBiotics provided NM002 doses for initial UK phase and developed scalable manufacturing process.
• Undisclosed NP213 Commercial PartnercoreChannel Partner/ Reseller/ Distributor · 26 February 2021Licensing agreement for NP213 peptide topical nail fungus treatment. Partner has exclusive rights in major territories including Europe and Japan (excluding US). Launch of product as medical device anticipated in 2022 via direct-to-consumer healthcare channels including retail pharmacies. NovaBiotics receives development milestone payments prior to launch and sales royalties thereafter.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• GSK: Global pharma with both a substantial anti-infectives portfolio (HIV, vaccines, respiratory) and a major consumer healthcare division. Indirect overlap across NovaBiotics' pharma and consumer health categories.
• Shionogi: Japanese global pharma with a major anti-infectives franchise (cefiderocol/Fetcroja for resistant Gram-negative infections) and broad pipeline. Overlaps with NovaBiotics on AMR antibacterial development and respiratory indications.

Direct peers

• Insmed: US commercial-stage biotech with ARIKAYCE (inhaled liposomal amikacin) for nontuberculous mycobacterial lung infection and a development pipeline for chronic lung diseases including CF. Direct competitor in inhaled respiratory anti-infectives.
• Destiny Pharma: UK AIM-listed clinical-stage anti-infectives company developing XF-platform antimicrobial agents targeting resistant bacterial infections. Comparable late-stage anti-infectives pipeline in a similar UK/EU regulatory context.
• Iterum Therapeutics: US clinical-stage anti-infectives company developing oral sulopenem for resistant urinary tract and other infections. Directly comparable AMR-focused development profile and regulatory pathway.
• Spero Therapeutics: US clinical-stage biotech developing antibiotics for multidrug-resistant bacterial infections, including tebipenem HBr. Direct comparable in the AMR-focused antibacterial development space.
• Moberg Pharma: Swedish specialty pharma focused on nail and skin conditions (Kerasal Nail, Nalox for onychomycosis). Direct competitor in the consumer nail health category where NovaBiotics' Tinexyl franchise competes.

Emerging players

• ContraFect: US clinical-stage biotech developing direct lytic agents (lysins) and other anti-infectives for drug-resistant infections including Staphylococcus aureus bacteremia. Comparable in novel-mechanism antibacterial pipeline development.
• Antabio: French clinical-stage antibacterial company developing metallo-beta-lactamase inhibitors and Pseudomonas-targeted therapies. Comparable early-stage AMR antibacterial development focus.
• BioVersys: Swiss clinical-stage antibacterial biotech developing treatments for drug-resistant infections and tuberculosis. Overlap with NovaBiotics' NP432 antibacterial and TB programs via the cysteamine platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/NovaBiotics
• Facebookfacebook.com/NovaBiotics
• LinkedInlinkedin.com/company/novabiotics-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaBiotics